Repligen

Repligen

Bioprocessing solutions for biologics manufacturing

Overview

Repligen provides products and services to support biotherapeutic manufacturing. It offers filtration, chromatography systems, process analytics, fluid management, and protein solutions that help develop and produce biologics such as cell and gene therapies, mRNA, monoclonal antibodies, antibody–drug conjugates, bispecific antibodies, and fusion proteins. Its offerings are designed to fit the full bioprocess workflow—from upstream filtration and purification to downstream analytics and process control—through a portfolio of systems, consumables, and services. Repligen differentiates itself by maintaining a broad, integrated suite of bioprocessing technologies and global manufacturing support across 22 sites, enabling clients to scale from development to commercial production. The company’s goal is to advance and accelerate the manufacturing of biologics by providing reliable, end-to-end solutions that streamline development and scale-up.

Significant Headcount Growth

About Repligen

Simplify's Rating
Why Repligen is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Biotechnology

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1981

Get referred to Repligen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $204 million, with 13% organic growth and 55% adjusted operating growth.
  • Management raised 2026 guidance to $813-$835 million revenue and $2.03-$2.09 adjusted EPS.
  • BioLife expects $20 million year-one synergies and accretion by at least five cents.

What critics are saying

  • Repligen's BioLife deal needs approvals, or the $1.5 billion thesis breaks by Q4 2026.
  • Gene therapy headwinds, ATF issues, and Polymem hurt organic growth by roughly four points.
  • If integration stalls, Cytiva and Sartorius keep owning bioprocessing workflows and pricing power.

What makes Repligen unique

  • Repligen supplies Protein A ligands into Cytiva and MilliporeSigma OEM resin franchises.
  • Its July 2026 BioLife acquisition adds 18 approved therapies and recurring biopreservation consumables.
  • Repligen's Breda, Waltham, and Tokyo innovation centers embed it directly with customers.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.1B

Above

Industry Average

Funded Over

5 Rounds

Post IPO Convertible funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Convertible Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

↑ 29%

1 year growth

↑ 29%

2 year growth

↑ 29%
Scientist Live
Sep 10th, 2026
Analysis of the 2026 chromatography consumables market.

Analysis of the 2026 chromatography consumables market. Published: 10 September 2026 The global chromatography consumables market is projected to increase from US$6.0 billion in 2026 to US$9.7 billion by 2035, representing a compound annual growth rate of approximately 5.6% during the forecast period. Market expansion is being supported by rising pharmaceutical and biopharmaceutical research and development, increased biologics manufacturing, stricter testing requirements, and sustained investment in laboratory automation. This is according to a new report called 'Chromatography Consumables Market by Product, Chromatography Technique, End User, and Geographical Regions - Trends and Forecast Till 2035' from ResearchAndMarkets.com. Chromatography consumables market growth and trends Pharmaceutical and biotechnology companies account for a significant share of chromatography consumables demand. Columns, syringe filters, tubes, fittings, vials, well plates, purification resins, and related products are used throughout drug discovery, process development, analytical validation, quality control, lot release, stability testing, and commercial manufacturing. Growth in advanced biologics, biosimilars, vaccines, cell therapies, and gene therapies is accelerating demand for modality-specific purification products. Suppliers are introducing specialised affinity and ion-exchange resins for adeno-associated virus vectors, plasmid DNA, and other advanced therapy workflows. Repligen Corporation, for example, has introduced AVIPure affinity resins and HiPerT anion-exchange resins for gene therapy and viral vector purification applications. Food safety, environmental monitoring, clinical diagnostics, forensic analysis, petrochemical testing, and chemical analysis are also expanding the addressable market. Regulatory testing for pesticide residues, mycotoxins, allergens, adulterants, heavy metals, persistent pollutants, and volatile compounds requires recurring purchases of application-specific columns, high-purity solvents, filtration products, and solid-phase extraction cartridges. Key market drivers * Increasing pharmaceutical and biopharmaceutical R&D expenditure * Expansion of biologics, vaccine, biosimilar, cell therapy, and gene therapy pipelines * Growing adoption of automated and high-throughput analytical workflows * Stricter food safety, environmental monitoring, and quality-control regulations * Rising demand for pre-packed and single-use chromatography columns * Development of bio-inert, micro-volume, and solvent-efficient consumables Digitalisation is creating additional opportunities across the chromatography consumables market. Radio-frequency identification and other tracking technologies are increasingly being integrated into columns and guard cartridges to monitor injection counts, pressure history, and solvent volumes. These capabilities can strengthen workflow control, improve consumable management, and reduce unplanned analytical failures. Market challenges High product costs remain a barrier, particularly for smaller laboratories, academic institutions, and facilities operating under restricted budgets. Specialty columns and purification resins can require frequent replacement, increasing total operating expenditure. The industry also relies on a concentrated global supply base for silica, specialty polymers, and high-purity solvents, exposing manufacturers and end users to supply disruptions, price volatility, and longer procurement cycles. Chromatography consumables market segment highlights By product, columns are expected to account for the largest market share through 2035. Their central role in analytical and purification workflows, combined with recurring replacement requirements, supports a durable revenue base. The syringe filters segment is forecast to record a higher growth rate as demand increases for sample cleanup, sterile filtration, and pre-injection processing. By technique, liquid chromatography is projected to retain the largest share of the global chromatography consumables market. Its broad use in pharmaceutical, food and beverage, environmental, and biopharmaceutical laboratories continues to support demand for columns, solvents, filters, fittings, and sample-handling products. Gas chromatography is anticipated to expand at a comparatively higher rate, supported by environmental testing, petrochemical analysis, food safety programs, and forensic applications. Pharmaceutical and biotechnology companies are expected to remain the leading end-user segment. Environmental agencies are projected to experience faster growth as monitoring programs expand for drinking water, soil, air pollutants, and regulated contaminant classes such as per- and polyfluoroalkyl substances. Regional market outlook North America is expected to maintain the largest share of global chromatography consumables market revenue. The region benefits from a strong biopharmaceutical research ecosystem, extensive regulated manufacturing capacity, established laboratory infrastructure, and stringent quality standards across the United States and Canada. Asia-Pacific is forecast to register a higher CAGR through 2035. Growth is being supported by biopharmaceutical capacity expansion, regulatory modernisation, increased contract development and manufacturing activity, and continued investment in food, environmental, clinical, and academic testing laboratories across China, India, Japan, South Korea, and Australia. Competitive landscape Leading companies operating in the chromatography consumables market include: * Agilent Technologies * Bio-Rad Laboratories * JASCO * Millipore Sigma * Revvity * Sartorius * Shimadzu Scientific Instruments * Thermo Fisher Scientific Competitive strategies increasingly focus on specialised purification chemistries, pre-packed columns, single-use products, digitally enabled consumables, strategic acquisitions, and complete workflow portfolios. Recent industry activity also reflects consolidation in specialty downstream processing and sample preparation. Companies are pursuing acquisitions and portfolio investments to strengthen intellectual property, expand chromatography resin capabilities, and provide more integrated analytical and bioprocessing solutions. Market research coverage The chromatography consumables market report provides revenue forecasts and opportunity assessments by product, chromatography technique, end user, and geography. Product coverage includes columns, syringe filters, tubes and fittings, vials and well plates, and other consumables. Technique coverage includes liquid chromatography, gas chromatography, thin-layer chromatography, and additional chromatographic methods. The research evaluates market drivers, restraints, opportunities, competitive forces, patents, partnerships, investments, and recent industry developments. It also includes company profiles and insights from technical directors, product managers, analytical chemists, consultants, research scientists, and other industry stakeholders. Strategic value The report is designed to support manufacturers, distributors, channel partners, investors, and business development teams evaluating opportunities in the global chromatography consumables market. It provides data-driven insight into customer demand, competitive positioning, regional expansion, emerging applications, and high-growth market segments. Purchasers also receive analytical data packs, supporting insights, report customisation options, a research-team walkthrough, and an eligible complimentary update for reports more than six months old.

Yahoo Finance
Aug 28th, 2026
Limbach's 20% EPS growth outpaces revenue, while Veralto and Repligen fall short

Veralto and Repligen are two profitable stocks that face significant challenges, according to StockStory's analysis. Veralto, spun off from Danaher in 2023, has posted muted 4.6% annual revenue growth over five years, with estimated sales growth of just 6.5% for the next 12 months. The water analytics company trades at 21.8x forward P/E. Repligen, a bioprocessing technology manufacturer, has seen its adjusted operating margin fall by 16.2 percentage points over five years. Earnings per share have contracted 3.8% annually during that period, whilst returns on capital have diminished. The stock trades at 79.4x forward P/E. In contrast, Limbach, which provides building systems solutions, has delivered 15.6% annual revenue growth over two years, with earnings per share growth of 20% outpacing revenue gains.

Yahoo Finance
Jul 28th, 2026
Repligen lifts 2026 guidance with Q2 revenue up 12% to $204M, eyes BioLife deal

Repligen Corporation reported second-quarter revenue of $204 million, up 12% year over year, with 13% organic growth. Adjusted earnings per share rose to $0.54 from $0.37. The company raised its full-year 2026 guidance, now expecting revenue between $813 million and $835 million, representing reported growth of 10% to 13%. Adjusted diluted EPS is projected to range from $2.03 to $2.09. Adjusted operating margin improved to 16.7% from 12.0%, reflecting stronger profitability. Management attributed the performance to continued order momentum, portfolio diversification, and disciplined execution. Repligen also highlighted its pending acquisition of BioLife Solutions, which will strengthen its position in the cell therapy market by adding a recurring consumables business with established customer relationships.

Yahoo Finance
Jul 28th, 2026
Repligen beats Q2 expectations with $204M revenue and 54 cents per share earnings

Repligen reported second-quarter profit of $5 million, or 9 cents per share. Adjusted earnings came to 54 cents per share, beating Wall Street expectations of 45 cents per share. The Waltham, Massachusetts-based drug developer posted revenue of $204.1 million in the period, surpassing analyst forecasts of $201.9 million. The company expects full-year earnings in the range of $2.03 to $2.09 per share. The results exceeded estimates from analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.

BioLife Solutions, Inc.
Jul 22nd, 2026
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media

WALTHAM, Mass. and BOTHELL, Wash., July 22, 2026 -- Repligen Corporation (NASDAQ: RGEN, “Repligen,” or “the Company”), a life sciences company focused on bioprocessing technology...

Recently Posted Jobs

Sign up to get curated job recommendations

Repligen is Hiring for 59 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →